ResMed (RMD) – Research Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of ResMed (NYSE: RMD) recently:

• 2/9/2026 – ResMed was upgraded by analysts at Weiss Ratings from a “hold (c+)” rating to a “buy (b-)” rating.
• 2/7/2026 – ResMed was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 2/2/2026 – ResMed had its price target raised by analysts at Citigroup Inc. from $330.00 to $345.00. They now have a “buy” rating on the stock.
• 1/30/2026 – ResMed had its price target raised by analysts at Royal Bank Of Canada from $311.00 to $314.00. They now have an “outperform” rating on the stock.
• 1/30/2026 – ResMed had its price target raised by analysts at Stifel Nicolaus from $260.00 to $265.00. They now have a “hold” rating on the stock.
• 1/30/2026 – ResMed had its “overweight” rating reaffirmed by analysts at KeyCorp. They now have a $302.00 price target on the stock.
• 1/30/2026 – ResMed was given a new $281.00 price target on by analysts at Robert W. Baird.
• 1/30/2026 – ResMed had its price target raised by analysts at Piper Sandler from $270.00 to $275.00. They now have a “neutral” rating on the stock.
• 1/30/2026 – ResMed had its price target raised by analysts at Wells Fargo & Company from $265.00 to $270.00. They now have an “equal weight” rating on the stock.
• 12/29/2025 – ResMed had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – ResMed had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/18/2025 – ResMed had its price target lowered by analysts at Stifel Nicolaus from $270.00 to $260.00. They now have a “hold” rating on the stock.
• 12/16/2025 – ResMed had its “neutral” rating reaffirmed by analysts at Robert W. Baird. They now have a $275.00 price target on the stock, down previously from $300.00.
• 12/16/2025 – ResMed was downgraded by analysts at Robert W. Baird from a “strong-buy” rating to a “hold” rating.
• 12/15/2025 – ResMed had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.

ResMed Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 19th. Investors of record on Thursday, February 12th will be issued a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.9%. The ex-dividend date is Thursday, February 12th. ResMed’s payout ratio is 23.74%.

Insider Activity at ResMed

In other ResMed news, CEO Michael J. Farrell sold 4,991 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $273.78, for a total transaction of $1,366,435.98. Following the transaction, the chief executive officer directly owned 466,223 shares in the company, valued at $127,642,532.94. This represents a 1.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Witte Jan De sold 2,055 shares of the firm’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $255.00, for a total value of $524,025.00. Following the transaction, the director owned 4,261 shares of the company’s stock, valued at approximately $1,086,555. This represents a 32.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 18,137 shares of company stock worth $4,658,832. Company insiders own 0.65% of the company’s stock.

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.